Breakthrough invasive fungal infections on isavuconazole prophylaxis in hematologic malignancy & hematopoietic stem cell transplant patients.

Akshay M Khatri Yoichiro Natori Anthony D Anderson Ra'ed JabrShreya A ShahAkina NatoriNamrata S ChandhokKrishna KomanduriMichele I MorrisJose Fernando CamargoMohammed Raja

Published in: Transplant infectious disease : an official journal of the Transplantation Society (2023)

ISA prophylaxis was associated with a significant cumulative incidence of bIFIs. Despite the appealing side-effect and drug-interaction profile of ISA, clinicians must be vigilant about the potential risk for bIFIs.

Keyphrases

hematopoietic stem cell
end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
palliative care
prognostic factors
risk factors
emergency department
human health
adverse drug